LON:GENI GENinCode Share Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding GENinCode plc Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume54,271 shsAverage Volume71,738 shsMarket Capitalization£18.21 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsHeadlinesOptions Chain Receive GENI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GENinCode and its competitors with MarketBeat's FREE daily newsletter. Email Address GENI Stock Forecast (MarketRank)Overall MarketRank™0.00 out of 5 starsAnalyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 - 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for GENinCode. Previous Next 0.0 Community Rank Outperform VotesGENinCode has received 0 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGENinCode has received 0 “underperform” votes. (Add your “underperform” vote.)MarketBeat's community ratings are surveys of what our community members think about GENinCode and other stocks. Vote “Outperform” if you believe GENI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GENI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGENinCode does not currently pay a dividend.Dividend GrowthGENinCode does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GENinCode insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of GENinCode is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GENinCode is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About GENinCodeGENinCode Plc engages in the development and commercialization of clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The company's molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a patented genetic test to help user to adopt cardiovascular prevention steps; Lipid inCode, a genetic diagnostic test, which analyzes the seven genes associated with familial hypercholesterolemia; SUDD inCode, a genetic test to diagnose the cause of sudden cardiac death and familial heart disease; Thrombo inCode, a genetic test that analyzes 12 genetic variants related to hereditary thrombophilia and the risk of thrombosis; and Thrombo inCode Reproductive Health, a genetic test that offers information related to risk of thrombophilia and associated risks for future pregnancies. GENinCode Plc was incorporated in 2018 and is based in Oxford, the United Kingdom.Read More GENI Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Industry, Sector and Symbol Stock ExchangeLON Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolLON:GENI CUSIPN/A CIKN/A Webwww.genincode.com Phone44 1865 955 847FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio18.02 Quick Ratio17.83 Sales & Book Value Annual Sales£1.15 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.33 Book ValueGBX 14.30 per share Price / BookN/AMiscellaneous Outstanding Shares95,817,000Free FloatN/AMarket Cap£18.21 million OptionableOptionable BetaN/A GENinCode Frequently Asked Questions Who are GENinCode's key executives? GENinCode's management team includes the following people: Mr. Matthew Heaton Walls, Co-Founder, CEO & Director (Age 58, Pay $259.07k)Mr. Jordi Puig Gilberte, Co-Founder, COO & DirectorMr. Paul Andrew Peter Foulger, CFO, Company Sec. & Director (Age 52, Pay $126.42k) Who are some of GENinCode's key competitors? Some companies that are related to GENinCode include Akumin (AKU), SQI Diagnostics (SQD), Oncimmune (ONC), Yourgene Health (YGEN), Verici Dx (VRCI), VentriPoint Diagnostics (VPT), Cambridge Cognition (COG), GeneNews (GEN), LexaGene (LXG), genedrive (GDR), LED Medical Diagnostics (LMD), Abingdon Health (ABDX), Integrated Diagnostics (IDHC), Deepmatter Group (DMTR) and 3D Signatures (DXD). View all of GENI's competitors. What is GENinCode's stock symbol? GENinCode trades on the London Stock Exchange (LON) under the ticker symbol "GENI." How do I buy shares of GENinCode? Shares of GENI and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. How much money does GENinCode make? GENinCode (LON:GENI) has a market capitalization of £0.00 and generates £1.15 million in revenue each year. How can I contact GENinCode? The official website for GENinCode is www.genincode.com. The company can be reached via phone at 44 1865 955 847. This page (LON:GENI) was last updated on 6/29/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here